



2016 CABA Biomedical **Investment & Entrepreneurship** Symposium

Concurrent Program
1:1 Partnering
See Page 8-9



- **Crossing-Border Biomedical Investments**
- **Driving Biomedical Innovation**
- **Wealth Management & Biomedical Investment**
- **Biomedical Ventures**



CHAIR

KEVIN FANG

CO-CHAIRS

ELLEN FAN JIAN SHAO ZHENDONG ZHU

PRESIDENT

ERIC SHI

COMMITTEE MEMBERS

LAN CAO	QINGQING CAO	QINGLIN CHE	YIN CHEN
ZHIHONG CHEN	CHAOYANG DAI	SHUJIA DANIEL DAI	ELLEN FAN
JIANFENG JEFF HANG	JO LEE	HAO HOWARD LI	SHIWEN LIN
CARRIE LIU	SUSAN QU	ERIC SHI	XUE SHUI
ZHIGANG WANG	LI XING	WENDY YANG	ZHIYONG YANG
BO YING	CHUNXIAO YU	XIANG YANG YU	YOUXIN ZHANG
XIAOYONG ZHAO	LIPING ZHOU		





Agenda

9:00am-9:30am **Registration and Refreshment**

9:30am-9:35am **Opening Remarks**

Kevin Fang, Ph.D., Symposium Chair, President-Elect, CABA

9:35am-9:45am **Welcome Address**

Eric Shi, Ph.D., President, CABA

Session I **Crossing-Border Biomedical Investments**

Session Chair: *Youxin Zhang, Ph.D.*

9:45am-10:20am "Biotech Deal Making: Does Crossing Borders Make a Difference?"

David-Alexandre "DA" Gros, M.D., MBA, SVP and Chief Business Officer, Alnylam Pharmaceuticals

10:20am-10:55am "China's New Generation of Venture Capital"

Steven Wang, MBA, CFA, Managing and Founding Partner, Highlight Capital

10:55am-11:30am "Fundamental Analysis in Biotech Investing"

Bihua Chen, MSc., MBA, CEO, and Portfolio Manager, Cormorant Asset Management.

11:30am-12:00pm **Crossing-Border Initiatives**

Hosted by *Lan Cao, Ph.D.*

"Introduction of Shenzhen: Opportunity for Entrepreneurship"

Paul Xu, MIBS, Business Development Consultant, North America Representative Office of Shenzhen

"Simcere: Pioneer the Healthcare Frontier"

Hua Mu, M.D., Ph.D., CSO, R&D President, Simcere Pharmaceutical Group

12:00pm-1:15pm **Lunch Break** *Sponsored by*  中国深圳市驻北美经贸代表处
NORTH AMERICAN REPRESENTATIVE OFFICE OF SHENZHEN, CHINA

Session II **Driving Biomedical Innovation**

Session Chair: *Wendy Yang, MBA*

1:15pm-1:45pm "KPC Perspective on Changing Health Care Landscape and Evolving Pharma Strategy in China"

Xiaochang Dai, Ph.D., CEO, Kunming Pharmaceutical Corporation



- 1:45pm-2:15pm “Expanding Innovation Partnering with Academia”
Michael Draper, MSc., Ph.D., RAC, Senior Director, Sanofi External Science & Partnering - East Coast
- 2:15pm-2:45pm “NetVation: Together We Innovate!”
Yuan-Hua Ding, Ph.D., Executive Director and Head of Pfizer External R&D Innovation (ERDI) and **Libing Yu, Ph.D.**, Venture Partner of Anlongmed Fund and CEO of NetVation (HK) Limited
- 2:45pm-3:05pm Coffee Break
- 3:05pm-3:15pm 2016 CABA High School Student Awards Announcement
Susan Qu, Ph.D., MBA, Immediate Past President, CABA

Session III Wealth Management and Biomedical Investment

Session Chair: **Ellen Fan, MSc.**

- 3:15pm-4:15pm Panel Discussion: Investment in Biotech and Pharmaceutical Sectors
 Panelists:
Stuart Berzin, Private Wealth Relationship Manager, Merrill Lynch Private Banking and Investment Group
David D. Lu, MSc., President & CIO, Summit Investments Group
Gwen Ren, MSc., Portfolio Manager, and Certified Financial Planner, Morgan Stanley

Session IV Biomedical Ventures

Session Chair: **Jian Shao, MBA**

- 4:15pm-5:15pm Panel Discussion: Healthcare VC Landscape and Trend in US & China
 Panelists:
Sean Cao, Ph.D., VP of Global Business Development, Simcere Pharmaceutical Group
Fred Mermelstein, Ph.D., Managing Director, Ascentia Health Care Fund
Ricky Sun, Ph.D., Principal, Bain Capital Life Science Fund

Session V Investors-Entrepreneurs Partnership

Session Chairs: **Jian Shao, MBA** and **Zhihong Chen, Ph.D.**

- 10:00am-4:00pm 1 on 1 Partnering
- 5:15pm-6:00pm Refreshment and Networking



Speakers



David-Alexandre Gros, M.D.

Dr. Gros joined Alnylam in 2015 with extensive experience in the pharmaceutical industry and in healthcare investment banking and strategy consulting. In his current role, he is a member of the Management Board and is responsible for Alnylam's finance, business development, investor relations, and communications functions. Most recently, he served as Executive Vice President and Chief Strategy Officer at Sanofi, where he was a member of the Executive Committee. Prior to Sanofi, he held positions of increasing responsibility in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. Dr. Gros holds an M.D. from the Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School, and a B.A. from Dartmouth College.



Steven Wang, MBA, CFA

Prior to founding HighLight, Steven was general partner and Investment Committee Member at CDH, one of China's largest private equity firms

Before that, Steven was the Director of Healthcare at Avenue Capital, Analyst at Lehman Brothers in London and Manager of M&A at Becton Dickinson Group, where he was promoted three times.

During the last ten years, Steven was responsible for transactions totaling over \$800M, including mergers and acquisitions, corporate restructuring, early and growth stage company investments.

Steven's past notable deals include: Kang Hong Pharma, Poly, Angel Women and Children's Hospital, New Century Children's Hospital, Kang Ning, New Eyes (430140), Evercare, King-Yee, TriPath Imaging, Inc. (NASDAQ: TPTH).

Steven received his MBA from London Business School, Master of Bio-Chemistry and Ph.D. qualification from NYU, and bachelor's degree from Chinese Science and Technology University.



Fred H. Mermelstein, Ph.D.

Dr. Mermelstein is the founder of several biotechnology companies, and has had substantial management experience with numerous biotech start-up companies.

Dr. Mermelstein currently is a Managing Director for the Ascentia Health Care Fund and serves on several boards, including Advantagene, Inc., NX PharmaGen, INc., Linus Oncology, Inc., and Raqia, Inc., the most recent company he co-founded. In addition, since 2004, Dr. Mermelstein is an Adjunct Assistant Professor in the Department of Molecular Genetics, Microbiology and Immunology at UMDNJ-Robert Wood Johnson Medical School, and Entrepreneur-in-Residence at Dana Farber Cancer Center.



Dr. Mermelstein was the founder of Javelin Pharmaceuticals, Inc. (JAV), which was recently acquired by Hospira, Inc. He has served as the CEO and President of Javelin, which has brought to market in Europe Dyloject™, an injectible anti-inflammatory for the treatment of post-operative pain. He was the founder of PolaRx Biopharmaceuticals, Inc., where he also served as Chief Scientific Officer, and was responsible for bringing Trisenox™ (Arsenic Trioxide for the treatment of Acute Promyelocytic Leukemia) to NDA completion, now marketed and sold worldwide.

Dr. Mermelstein has formerly served in numerous biotech and venture capacities, including Director of Venture Capital at Paramount Capital Investments, LLC., (overseeing all technology evaluation and licensing opportunities) and as General Partner of The Orion Biomedical Fund (private equity fund). Additionally, Dr. Mermelstein has served on the boards of several private as well as public companies including Cardiome Pharma (CRME), and nonprofit institutes, including the Rogosin Institute and Jordan Heart Foundations.

Dr. Mermelstein was selected as a financial advisor to the New York City Emerging Industries Fund and Technology Transfer Seed Fund of the New York Economic Development Corporation for the biopharmaceutical sector.

Dr. Mermelstein received a Ph.D. joint degree in pharmacology and toxicology at Rutgers University and University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School (UMDNJ-RWJ) and completed his post-doctoral training as a research fellow of the Howard Hughes Medical Institute located at UMDNJ-RWJ and BS, MS in Toxicology from Northeastern University. Dr. Mermelstein is the recipient of research awards from the Howard Hughes Medical Institute, National Institute of Health/National Cancer Institute and New Jersey Cancer Commission, and the Society of Toxicology. Dr. Mermelstein is the author of numerous scientific publications in peer-reviewed journals and holds several primary patents.

Bihua Chen, MBA

Bihua Chen is CEO and Portfolio Manager at Cormorant Asset Management. Ms. Chen founded Cormorant Asset Management LLC ("Cormorant") in 2013 and currently manages investments in public and private biopharmaceutical companies totaling over \$800m. Prior to founding Cormorant, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. Ms. Chen obtained an MBA from the Wharton School of Business in 1998 and graduated with a Master of Science, Molecular Biology, from the Graduate School of Biomedical Science at Cornell Medical College in 1994. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China, which she received in 1990.

Xiaochang Dai, Ph.D.

Dr. Xiaochang Dai is the CEO of KPC Pharmaceutical Inc., which is one of the major players in China. Dr. Dai was the GM of KBN, a joint venture of TEVA and KPC in China for more than ten years. Prior to join KBN, Dr. Dai was the chairman of Walvax, a leading vaccine company in China. Dr. Dai received his Ph.D. in The Scripps Research Institute USA, and also did a postdoctoral research at California Institute of Technology. Dr. Dai has involved actively in the bio-pharmaceutical academic and industry in China, and has been a leading figure of Chinese pharmaceutical industry for almost twenty years.



**Michael P. Draper, MSc., Ph.D.**

Dr. Michael Draper is currently the Senior Director of External Science and Partnering and a member of the Science, Strategy & External Innovation and Science Policy group at Sanofi. He has more than 15 years of research and development experience in the pharmaceutical industry at both large and small pharmaceutical companies. After completing his postdoctoral studies, he joined the organization that later became Aventis Pharmaceuticals as a Senior Scientist. In 2000, he joined Paratek Pharmaceuticals. During his time at Paratek, he managed discovery, clinical operations, and regulatory affairs and advanced multiple compounds into the clinic. He has been the Principal Investigator for Phase I and II SBIR grants and an Investigator on a Bill and Melinda Gates foundation grant to discover new tetracyclines for filariasis. Dr. Draper has held several adjunct faculty positions throughout his career. He received his MSc. degree from the University of Connecticut and his Ph.D. in Genetics from the University of New Hampshire. He conducted his postdoctoral work at Tufts University with Dr. Stuart Levy. He has his Regulatory Affairs Certification and is an inventor on multiple patents. In his current role at Sanofi he is responsible for setting up partnerships with major academic and medical institutions, biotechnology companies, and disease foundations.

**Yuan-Hua Ding, Ph.D.**

Dr. Yuan-Hua Ding is an Executive Director and Head of Pfizer External R&D Innovation (ERDI) - Asia/Pacific, Pfizer Worldwide Research & Development (WRD). He is also a member of the ERDI leadership team. In this capacity, he partners with colleagues in ERDI, Pfizer Business Development Group and Pfizer Asia Country Offices to evaluate technologies and assets from Asia Pacific academic, biotech & pharma laboratories, seek opportunities to incubate early biotech companies, build and manage a research network of academic institutes, biotech & pharma companies, and venture capital groups as well as regional bioparks. He liaises with therapeutic area and technology research unit leaderships in accessing the sciences, technologies and products needed to support Pfizer R&D mission.

Prior to his current job, Dr. Ding served a variety of roles in the Pfizer R&D division, including Head of Asia External Science and Technology, Head of Structural Biology at the RTC Research Technology Center (RTC) in Cambridge, MA, Associate Research Fellow and Senior Research Scientist. As the Head of the RTC Structural Biology, he oversaw a group of scientists responsible for protein production, characterization, crystallization, crystallography and structure-based drug design. His group supported structural based drug design portfolio of 10+ programs, through collaborative efforts with RTC, Pfizer global structural biology groups and therapeutic area project teams, covering oncology, diabetes, inflammation and CNS. He also served as project leaders for several drug discovery programs.

Dr. Ding received a bachelor's degree in Electronic Engineering from Peking University in 1987 and a master's degree in Biophysics from Tsinghua University in 1990. In 1996, after completing his doctoral studies in Biochemistry with Prof. John Rosenberg and Roger Hendrix at the University of Pittsburgh, he moved to Harvard University to be a postdoctoral fellow with Prof. Don Wiley. Dr. Ding's postdoctoral work focused on




structural and biophysical aspects of molecular interactions among T-cell receptor (TCR), major histocompatibility complex (MHC) and peptide antigens. While in Dr. Wiley's Lab, Dr Ding also collaborated with Dr. Judah Folkman of Boston Children's Hospital on structural studies of endostatin, a protein shown to be a potent angiogenesis inhibitor in mouse model.

Libing Yu, Ph.D.



Libing Yu is venture partner of Anlongmed Fund, and CEO of NetVation (HK) Limited, focusing on incubating new ventures of drug discovery, and technology development. NetVation has headquarters in Beijing with subsidiaries in Hong Kong, Boston and Hangzhou exploring technologies and pre-clinical and clinical assets from Asia and North America's academic institutes, biotech, CRO and CMOs. Prior to this, Libing was founder and CEO of Alputon (Shanghai) PharmaTech Co. Ltd., and utilized the advanced chemistry technology platform to provide drug design, medicinal chemistry, process chemistry, and CMC services to global pharma and biotech companies and advanced several INDs to clinical development stage. From 1997 to 2006, Libing took different roles with increasing responsibilities and lastly as director of chemistry at ArQule Inc.

Stuart Berzin



Mr. Berzin has been a partner in The Sharma Group since joining Merrill Lynch in 2009. He assists in developing new client relationships and managing existing ones, in addition to creating wealth management strategies. Mr. Berzin is a specially qualified Portfolio Manager who, in addition to providing traditional advice and guidance, can help clients pursue their objectives by building and managing personalized portfolio strategies utilizing the entire open architecture platform at Merrill Lynch.

Prior to joining Merrill Lynch, Mr. Berzin worked in the executive search business helping to build teams within the private banking and high-net-worth industry.

Mr. Berzin earned his bachelor's degree in economics from Lehigh University. He is a member of the American Technion Society, and resides in Newton, Massachusetts.

The Sharma Group has been recognized by Barron's Magazine as one of America's Top 100 Wealth Advisors for the past 13 consecutive years, as well as one of America's Top 100 Wealth Advisors by Forbes Magazine.

Gwen Ren, CFP®



Gwen has worked for several global banking and investment firms including bank of America, Citigroup, and Morgan Stanley. She earned B.A in Economics from University of International Business & Economics in Beijing, M.S in Information System from the Engineering School of Northeastern University in Boston. Gwen was born in China, worked for the Ministry of Foreign Economic Relations & Trade of China (currently Ministry of Commerce of China), and travelled extensively around the world before she came to United States.



Gwen loves working at Morgan Stanley, for its brand name, rich resources, impeccable financial planning teams and competitive investment management services. Her disciplined technical background provides her a unique set of skills for understanding her clients' needs and creating customized portfolios to meet those needs. Her clients came from all over the world.

For her spare time, she enjoys TV shows, Yoga, and Biking, currently a resident of Massachusetts.



David D. Lu, MSc.

Phone: (617) 960-7065

Email: DavidLu88@gmail.com

Mr. Lu received his Master's Degree in Electrical Engineering in collaboration with the Chemistry Department at Tufts University.

Then David worked on developing a fluorescent stained single cell 3-D imaging system in collaboration with the UMass Medical School in Worcester.

David then started his own consulting company providing services to medical device, instrument and other companies.

Later, David worked at Bank of America, Fidelity Investments, Putnam Investments.

Currently, David is the President and Chief Investment Officer (CIO) of Summit Investments Group investing in biopharm drug discovery, medical device, diagnosis and other industries.



ABOUT

The concurrent program “CABA 1:1 Partnering” is an effective way to connect investors and entrepreneurs/companies. It features half-hour 1:1 private meetings between pre-selected high quality entrepreneurs/-companies. Meetings are pre-scheduled through a two-way selection process and hosted in the satellite rooms next to the auditorium of the CABA Investment & Entrepreneurship Symposium.

THIS YEAR

- **10** prominent Venture Capitalists and **30** promising companies have joined already!

FEATURES

1:1 Partnering



**Investment,
In-Licensing and
Collaboration
Opportunities**

**Prominent
Capitalist
(from US)**

Promising Entrepreneurs (in US)

- Half hour
- Private
- Efficient
- On-site

Communicate directly with prospective investors and senior business and scientific management executives

INVESTORS

Rui Zhang, MBA

Managing Partner, Azia Healthcare Partners



Steven Wang, MBA, CFA

Managing and Founding Partner, Highlight Capital



Chong Xu, Ph.D.

Associate, F-Prime Capital



Zhiping Cui, MBA

Vice President, Shanghai Fosun Pharmaceutical (group) Co., Ltd.



Wei Zhao, Ph.D.

Associate, WuXi Healthcare Ventures



Sean Cao, Ph.D.

VP of Global Business Development, Sincere Pharmaceutical Group



Ricky Sun, Ph.D.

Principal, Bain Capital Life Science Fund



Mr. Jie Yin, M.Ec.

Executive Officer, Kaitai Capital and Kaitai Chuangfu Fund



Howard Yuwen, Ph.D.

Managing Partner, Genesun Biotech



Bihua Chen, MBA

CEO and Portfolio Manager, Cormorant Asset Management





Investors

Rui Zhang, MBA

Azia Healthcare Partners is an early to growth stage life sciences investment fund focusing on identifying and developing the next generation industry leaders. The investment team has over 40 years of private equity, venture capital and capital market experience and bring together a unique blend of skills in both US and China.

Rui Zhang, managing partner, four years biopharmaceutical research experience, six years healthcare investment experience in both US and China. Rui receives medicinal chemistry training at State University of New York, she also holds an MBA from Columbia Business School.

Chong Xu, Ph.D., MBA

Chong is an Associate at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company's Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

- See more at:

<http://fprimecapital.com/team-members/chong-xu/#sthash.wTmEIlmf.dpuf>



Zhiping Cui, MBA

Vice President of Shanghai Fosun Pharmaceutical (group) Co., Ltd., Director of Handa Pharmaceuticals, LLC. Mr. Cui has been at Fosun Pharma for 10 years and served as Vice President. He took lead of Fosun Pharma's VC Investment Division, held responsible for group pharmaceutical products exportation and for the overseas investment (M & A) as well as VC investment. Before joining Fosun Pharma, he was the Vice president of Shanghai Pharmaceutical Co., Ltd.

Mr. Cui received a Bachelor Degree of Pharmacology from Shanghai Medical University and a Master Degree of Business administration from the Business School of Australia La Trobe University.

Fosun Pharma

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), a leading healthcare company in China, established in 1994, and has been listed on Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 600196-SH,02196-HK).



**Wei Zhao, Ph.D.**

Dr. Wei Zhao is an Associate of WuXi Healthcare Venture which is a leading cross-border venture capital firm focused in the life sciences and healthcare, with offices in Boston and Shanghai. The firm has assembled a team of seasoned investors and company builders with deep roots in science, technology, and innovation. The firm's mission is to find, seed, and develop life science and healthcare businesses that can benefit the most from the firm's operational expertise, strategic support, capital, and the patience of a long-term perspective. Prior to joining WuXi, Dr. Wei Zhao worked as Senior Life Sciences Specialist at L.E.K. Consulting. Dr. Zhao has a Ph.D. in Neuroscience from Northwestern University, and was a postdoctoral Fellow at Massachusetts Eye and Ear Infirmary/Harvard Medical School.

**Sean Cao, Ph.D.**

Dr. Sean Cao is the VP of Global Business Development at Simcere Pharmaceutical Group, responsible for the global BD strategy for Simcere, including licensing, acquisition, partnering and investment activities. Dr. Cao is also the President and Board Director at Simcere of America, a wholly owned subsidiary of Simcere. Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D. In addition, Dr. Cao was also responsible for managing the evaluation of acquisition/in-licensing opportunities, directly responsible for the due diligence of multiple investment decisions worth more than \$4B. Before Sanofi, Sean was an associate at New Leaf Venture Partners, a leading healthcare VC firm based in New York. Sean worked in the pharmaceutical and diagnostic industries for over eight years before joining New Leaf, first at Aventis, then at Johnson & Johnson. Sean is a member of BayHelix, a premier organization of Chinese life sciences business leaders. Sean holds a Ph.D. in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.

**Howard Yuwen, Ph.D.**

Howard Yuwen, Ph.D. is currently the Managing Partner of Genesun Biotech LLP, an early-stage venture capital firm that invests in life science startup companies in the United States and China.

Howard has more than 30 years of pharmaceutical experience in clinical research, drug development and regulatory affairs. Howard specialized in regulatory science and operations, business strategies and corporate development. Prior to Genesun, Howard held senior management positions at Alexion, Shire HGT, CancerVax, Elan Biopharmaceuticals, and US FDA.





Ricky Sun, Ph.D.

Principal, Bain Capital Life Science Fund

Ricky Sun joined Bain Capital in 2016. Prior to joining Bain Capital, from 2013 to 2016 he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.

Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a BA in chemistry.



Jie Yin, M.Ec.

Mr. Jie Yin is an executive officer of Kaitai capital and Kaitai Chuangfu Fund. He oversees the investment in healthcare sector. He led and participated several deals including YULONG Biomedical Group (clinical test laboratory), Yun Pacs (platform of medical imaging), QY NODE (cloud-based genomic data management and bioinformatics platform), Purmed (healthcare service provider), icareTek (Intelligent monitoring device), Yunyin Medicine (cancer liquid biopsy), Carsgen (immuno-oncology) and so on. Mr. Yin obtained his master degree of economics from Zhejiang University.



Steven Wang, MBA, CFA

Managing and Founding Partner, Highlight Capital

**Steven is also a speaker and will give his talk "China's New Generation of Venture Capital" at 10:20 am. Please find his bio in page 3.*



Bihua Chen, MBA

CEO and Portfolio Manager, Cormorant Asset Management

**Bihua is also a speaker and will give her talk "Fundamental Analysis in Biotech Investing" at 10:55 am. Please find her bio in page 4.*



Seeking for Exceptional Talents

Simcere: Pioneer the Healthcare Frontier

Simcere is an integrated pharmaceutical group with leading development and commercial capabilities in China. Simcere is an emerging leader in R&D of innovative medicines and branded generics in China focusing on oncology, neurology, cardiovascular & metabolic diseases, Inflammation and Infectious diseases. In 2015, Simcere's translational medicine and innovative drug R&D platform has been recognized as a State Key Laboratory by the National Ministry of Science and Technology. Simcere has also been actively pursuing cross-border partnerships to bringing global innovation and brands to China. Simcere has been nominated as top 100 in China pharmaceutical industry and top 10 most innovative companies in China for many years. Simcere of America has set up two offices, in Boston - international business development, New Jersey - international pharmaceutical business.

BioSciKin: Help More People with Precision Medicine

BioSciKin is a China-based biotechnology company focusing on precision medicine, drug innovation, incubation, and investment. It is recognized by State Ministry of China as a National Start-up Space. BSK is developing innovative precision medicine products, and is looking for partnership from all over the world for investment and co-development opportunities. We have formed strong alliances with multiple global ventures and invested over 20 start-up companies world-wide.

Looking into the future, our aim is to build:

- An open investment and incubation platform of precision medicine
- A leading precision medicine clinical test laboratory
- A pioneer in innovative drug development and commercialization

Contact us:

e-mail: dongguowei@simcere.com

Company and contact Wechat



North American Representative Office of Shenzhen, P.R. China

The North American Representative Office of Shenzhen, P.R. China (NAROS) is a U.S. based business service provider representing the City of Shenzhen. Directly sponsored by the Shenzhen Municipal Government and invest Shenzhen, NAROS is to offer guidance and consultation to North American companies wishing to enter Chinese market by means of direct investment within the City of Shenzhen, as well as Shenzhen companies looking to enter North American market. In addition, NAROS serves as a liaison for the Shenzhen Municipal Government and acts as a point of contact for the economic related inquires on behalf of the municipal government.

Contact Us:

Tel: 1(626)796-0088

Email: info@shenzhenoffice.org

Web: www.shenzhenoffice.org





Conference Sponsors



Morgan Stanley



Cormorant Asset Management

AZIA Healthcare Partners



CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Please visit www.cabaweb.org for more info.

CABA



follow us on WeChat



The annual CABA Investment Symposium is a major event attracting prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and healthcare fields both locally and internationally.